作者
Pratik Ugare,Mallinath S. Kalshetti,Ashok Thulluru,Vrushabh Sunil Patil,Bahubali Patil
摘要
INTRODUCTION/OBJECTIVE: Migraine is a prevalent neurological condition characterised by headaches and other related symptoms, which severely impact quality of life due to the failure to deliver drugs to the brain and side effects related to the Blood-Brain Barrier (BBB). Nasal drug delivery is an alternative non-invasive route to the brain, bypassing the BBB. Cubosomes, lipid-based nanocarriers with exclusively cubic phase structures, have attracted interest as nasal delivery vehicles due to their biocompatibility, mucoadhesive properties, and ability to entrap both hydrophilic and hydrophobic drugs. METHODS: A systematic literature search was conducted in PubMed, Scopus, and Web of Science for peer-reviewed studies on cubosome-based nasal gels, intranasal delivery, mucoadhesive in situ gels, nose-to-brain delivery, and migraine therapy. Keywords were combined using Boolean operators AND and OR. Records were screened by title, abstract, and full text, with duplicates and irrelevant or non-scholarly sources excluded. Eligible studies were qualitatively synthesized based on formulation approaches, delivery mechanisms, preclinical evidence, limitations, and translational prospects. RESULTS: Cubosome-based nasal formulations exhibit increased brain bioavailability, rapid absorption, and sustained drug delivery, which improve treatment outcomes in migraine models. Integration into in situ gels increases nasal residence time and reduces mucociliary clearance. Preclinical studies report minimal toxicity and good tolerability. Emerging multifunctional systems have the potential to deliver personalised, targeted treatment for migraines. DISCUSSION: Intranasal cubosome delivery systems have strong potential to overcome blood-brain barrier restrictions through nose-to-brain administration. Their cubic nanostructure is distinctive, enhancing drug loading, stability, and controlled release, while in situ gel incorporation increases residence time and mucosal adhesion. Preclinical evidence indicates improved therapeutic efficacy and low systemic toxicity. Nevertheless, additional optimisation and clinical trials are needed to establish long-term safety, scalability, and the feasibility of migraine management. CONCLUSION: Cubosome-mediated nasal delivery is a powerful and flexible system for braintargeted migraine therapy. To translate these promising systems into clinical practice, it will be essential to address formulation and manufacturing challenges and ensure rigorous clinical validation.